Company Filing History:
1 out of 82 
1 out of 15 Years Active: 2018
Title: The Innovations of Stefan Bleich
Introduction
Stefan Bleich is a notable inventor based in Munich, Germany. He has made significant contributions to the field of medicine, particularly in the area of antidepressant treatment. His innovative approach focuses on predicting patient responses to monoaminergic antidepressants.
Latest Patents
Stefan Bleich holds a patent titled "Susceptibility to and stratification for monoaminergic antidepressants." This invention outlines a method for predicting whether a patient will respond to a monoaminergic antidepressant. The method involves determining the DNA-methylation status of a brain-derived neurotrophic factor (BDNF) gene promoter in a patient sample. It attributes hypomethylation of the BDNF gene promoter to non-response and normal or hypermethylation to response to the treatment. Additionally, the patent includes a kit and its use in this predictive method.
Career Highlights
Throughout his career, Stefan Bleich has worked with prestigious institutions such as Medizinische Hochschule Hannover and Universitätsmedizin der Johannes Gutenberg-Universität Mainz. His work has been instrumental in advancing the understanding of antidepressant efficacy and patient stratification.
Collaborations
Stefan has collaborated with notable colleagues, including Helge Frieling and André Tadic. Their combined expertise has contributed to the development of innovative solutions in the field of mental health.
Conclusion
Stefan Bleich's contributions to the field of medicine through his patent and collaborations highlight his commitment to improving patient care in antidepressant treatment. His innovative methods pave the way for more personalized approaches in mental health therapy.